Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians

Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians

6 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Bradley E. Bernstein, MD @BradEBernstein @willflavahan of @MassGeneralNews answers how this affects clinicians on the cause of drug resistance found in a form of intestinal tumor.

__________

Most cases of gastrointestinal stromal tumor (GIST), a form of soft tissue cancer (sarcoma), are caused by gene mutations that can be treated effectively with drugs that inhibit the action of enzymes which promote rogue cancer.

But an estimated 10% to 20% of GISTs do not have any mutations detectable or targeted. Scientists in a partnership on cancer research in the Boston area have now explained mechanisms that allow the production of these hard-to-treat cancers and have identified approaches in laboratory experiments that could lead to successful new therapies.

The research, a joint effort by scientists at the Massachusetts General Hospital (MGH), the MIT and Harvard Broad Institute, the Dana-Farber Cancer Institute (DFCI) and the Harvard Medical School (HMS) Ludwig Center, is published in Nature journal.

Importantly, the investigators show how "epigenetic" changes - changes in how the code of genes is read by tumor cells that are not caused by genetic mutations - can lead to the development of GISTs and other cancers, and how it may be possible to short-circuit the cancer-causing machinery.

"Your genome consists of about 6 feet of DNA wrapped very carefully to fit into microscopic cells. One of the tricks that the cell uses to compact all of this DNA is to tie it up into little loops," says senior co-author Bradley E. Bernstein, MD, PhD, of MGH, Broad Institute and the Ludwig Center at Harvard.

He prefers the method of shoelaces, where a knot separates every carefully tied chain. In scientific terms, the "knot" in the cells is called an "insulator." He and his colleagues found that one of these insulators usually prevents a gene that causes cancer, FGF4, from coming into contact with a stretch of DNA with a powerful switch that turns on an unrelated gene. The cancer-causing gene and the shift are in different loops in normal cells and never come into contact with each other. The insulator is not active in some types of GIST, however, the loops combine into one, and the on-switch activates the cancer-causing FGF4 gene incorrectly.

Read here: https://www.oncologytube.com/video/cause-of-drug-resistance-found-in-a-form-of-intestinal-tumor

Up Next Autoplay
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
4 Views
ash 6 hours
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 6 hours
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 22 hours
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 1 day
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 1 day
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 1 day
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 1 day
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 1 day
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
2 Views
ash 1 day
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 1 day